Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Author(s): Oscar Arias-Carrion*, Emmanuel Ortega-Robles, Daniel Ortuno-Sahagun, Jesus Ramirez-Bermudez, Aya Hamid and Ali Shalash

DOI: 10.2174/0118715273314675240820191447

DownloadDownload PDF Flyer Cite As
Sleep-Related Disorders in Parkinson's Disease: Mechanisms, Diagnosis, and Therapeutic Approaches

Page: [132 - 143] Pages: 12

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Parkinson's Disease (PD) is frequently associated with a spectrum of sleep-related disorders, including insomnia, Excessive Daytime Sleepiness (EDS), REM sleep Behaviour Disorder (RBD), Restless Legs Syndrome (RLS), and Sleep-related Breathing Disorders (SBDs). These disorders significantly impact PD patients' Quality of Life (QoL) and present unique diagnostic and therapeutic challenges.

Methods: This review has explored the intricate relationship between PD and sleep-related disorders, emphasizing their distinctive features and underlying neurobiological mechanisms. It aimed to consolidate current knowledge to optimize clinical management and improve patient care. The profound impact of these disorders on QoL has been evaluated, along with precise diagnostic methodologies. Additionally, various therapeutic strategies, including pharmacological treatments, nonpharmacological interventions, and device-aided therapies, have been examined.

Results: Sleep-related disorders are prevalent among PD patients. Specifically, RBD exhibits a prevalence of 40-50%, often preceding the onset of motor symptoms, indicating its potential as an early marker of PD. Despite their significant impact on QoL, these non-motor symptoms are frequently under-recognized and inadequately managed in clinical practice. Pharmacological treatments, along with nonpharmacological interventions, like cognitive-behavioral therapy for insomnia and lifestyle modifications, have shown varied efficacy. Device-aided therapies have also demonstrated the potential to improve sleep-related disorders and overall non-motor symptom burden.

Conclusion: Effective management of sleep-related disorders in PD calls for personalized, comprehensive, and multimodal therapeutic approaches. This requires the collaborative efforts of neurologists, sleep specialists, psychiatrists, and other healthcare professionals. Future research should focus on the intricate relationship between PD and sleep disorders, aiming to develop innovative treatments and significantly improve patient outcomes.

Keywords: Parkinson's disease, sleep-related disorders, REM sleep behaviour disorder, daytime sleepiness, obstructive sleep apnoea, restless legs syndrome, quality of life.

Graphical Abstract

[1]
Moustafa AA, Chakravarthy S, Phillips JR, et al. Motor symptoms in Parkinson’s disease: A unified framework. Neurosci Biobehav Rev 2016; 68: 727-40.
[http://dx.doi.org/10.1016/j.neubiorev.2016.07.010] [PMID: 27422450]
[2]
Maggi G, Vitale C, Cerciello F, Santangelo G. Sleep and wakefulness disturbances in Parkinson’s disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. Sleep Med Rev 2023; 68: 101759.
[http://dx.doi.org/10.1016/j.smrv.2023.101759] [PMID: 36708642]
[3]
Suzuki K, Okuma Y, Uchiyama T, et al. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson’s disease: A multicentre cross-sectional study. J Neurol Neurosurg Psychiatry 2017; 88(11): 953-9.
[http://dx.doi.org/10.1136/jnnp-2017-316136] [PMID: 28847794]
[4]
Tall P, Qamar MA, Rosenzweig I, et al. The Park Sleep subtype in Parkinson’s disease: From concept to clinic. Expert Opin Pharmacother 2023; 24(15): 1725-36.
[http://dx.doi.org/10.1080/14656566.2023.2242786] [PMID: 37561080]
[5]
Schenck CH, Cochen de Cock V, Lewis SJG, Tachibana N, Kushida C, Ferri R. Partial endorsement of: “Video-polysomnography procedures for diagnosis of rapid eye movement sleep behavior disorder (RBD) and the identification of its prodromal stages: Guidelines from the International RBD Study Group” by the World Sleep Society. Sleep Med 2023; 110: 137-45.
[http://dx.doi.org/10.1016/j.sleep.2023.07.012] [PMID: 37579534]
[6]
de Bergeyck R, Geoffroy PA. Insomnia in neurological disorders: Prevalence, mechanisms, impact and treatment approaches. Rev Neurol (Paris) 2023; 179(7): 767-81.
[http://dx.doi.org/10.1016/j.neurol.2023.08.008] [PMID: 37620177]
[7]
Loddo G, Calandra-Buonaura G, Sambati L, et al. The treatment of sleep disorders in Parkinson’s disease: From research to clinical practice. Front Neurol 2017; 8: 42.
[http://dx.doi.org/10.3389/fneur.2017.00042] [PMID: 28261151]
[8]
Zhu K, van Hilten JJ, Marinus J. The course of insomnia in Parkinson’s disease. Parkinsonism Relat Disord 2016; 33: 51-7.
[http://dx.doi.org/10.1016/j.parkreldis.2016.09.010] [PMID: 27639814]
[9]
Schütz L, Sixel-Döring F, Hermann W. Management of sleep disturbances in parkinson's disease. J Parkinsons Dis 2022; 12(7): 2029-58.
[http://dx.doi.org/10.3233/JPD-212749] [PMID: 35938257]
[10]
Feng F, Cai Y, Hou Y, Ou R, Jiang Z, Shang H. Excessive daytime sleepiness in Parkinson’s disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 2021; 85: 133-40.
[http://dx.doi.org/10.1016/j.parkreldis.2021.02.016] [PMID: 33637423]
[11]
St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson’s Disease and other synucleinopathies. Mov Disord 2017; 32(5): 645-58.
[http://dx.doi.org/10.1002/mds.27018] [PMID: 28513079]
[12]
Iranzo A. The REM sleep circuit and how its impairment leads to REM sleep behavior disorder. Cell Tissue Res 2018; 373(1): 245-66.
[http://dx.doi.org/10.1007/s00441-018-2852-8] [PMID: 29846796]
[13]
Diaconu Ș, Falup-pecurariu O, Țînț D, Falup-Pecurariu C. REM sleep behaviour disorder in Parkinson’s disease (Review). Exp Ther Med 2021; 22(2): 812.
[http://dx.doi.org/10.3892/etm.2021.10244] [PMID: 34131435]
[14]
Alonso-Navarro H, García-Martín E, Agúndez JAG, Jiménez-Jiménez FJ. Association between restless legs syndrome and other movement disorders. Neurology 2019; 92(20): 948-64.
[http://dx.doi.org/10.1212/WNL.0000000000007500] [PMID: 31004074]
[15]
Trenkwalder C, Winkelmann J, Inoue Y, Paulus W. Restless legs syndrome—current therapies and management of augmentation. Nat Rev Neurol 2015; 11(8): 434-45.
[http://dx.doi.org/10.1038/nrneurol.2015.122] [PMID: 26215616]
[16]
Yu Q, Hu X, Zheng T, et al. Obstructive sleep apnea in Parkinson’s disease: A prevalent, clinically relevant and treatable feature. Parkinsonism Relat Disord 2023; 115: 105790.
[http://dx.doi.org/10.1016/j.parkreldis.2023.105790] [PMID: 37541789]
[17]
Hunt J, Coulson EJ, Rajnarayanan R, Oster H, Videnovic A, Rawashdeh O. Sleep and circadian rhythms in Parkinson’s disease and preclinical models. Mol Neurodegener 2022; 17(1): 2.
[http://dx.doi.org/10.1186/s13024-021-00504-w] [PMID: 35000606]
[18]
Gros P, Videnovic A. Overview of sleep and circadian rhythm disorders in parkinson disease. Clin Geriatr Med 2020; 36(1): 119-30.
[http://dx.doi.org/10.1016/j.cger.2019.09.005] [PMID: 31733692]
[19]
Amara AW, Chahine LM, Videnovic A. Treatment of sleep dysfunction in parkinson’s disease. Curr Treat Options Neurol 2017; 19(7): 26.
[http://dx.doi.org/10.1007/s11940-017-0461-6] [PMID: 28567500]
[20]
Zuzuárregui JRP, During EH. Sleep issues in parkinson’s disease and their management. Neurotherapeutics 2020; 17(4): 1480-94.
[http://dx.doi.org/10.1007/s13311-020-00938-y] [PMID: 33029723]
[21]
Schenck CH. REM sleep behavior disorder as a complex condition with heterogeneous underlying disorders: Clinical management and prognostic implications (Commentary). Sleep Breath 2022; 26(3): 1289-98.
[http://dx.doi.org/10.1007/s11325-022-02574-6] [PMID: 35239134]
[22]
Zahed H, Zuzuarregui JRP, Gilron R, Denison T, Starr PA, Little S. The neurophysiology of sleep in parkinson’s disease. Mov Disord 2021; 36(7): 1526-42.
[http://dx.doi.org/10.1002/mds.28562] [PMID: 33826171]
[23]
Zhai S, Cui Q, Simmons DV, Surmeier DJ. Distributed dopaminergic signaling in the basal ganglia and its relationship to motor disability in Parkinson’s disease. Curr Opin Neurobiol 2023; 83: 102798.
[http://dx.doi.org/10.1016/j.conb.2023.102798] [PMID: 37866012]
[24]
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017; 18(2): 101-13.
[http://dx.doi.org/10.1038/nrn.2016.178] [PMID: 28104909]
[25]
Siegel JM. The neurotransmitters of sleep. J Clin Psychiatry 2004; 65 (Suppl. 16): 4-7.
[PMID: 15575797]
[26]
Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science 2013; 342(6156): 373-7.
[http://dx.doi.org/10.1126/science.1241224] [PMID: 24136970]
[27]
Eide PK, Vinje V, Pripp AH, Mardal KA, Ringstad G. Sleep deprivation impairs molecular clearance from the human brain. Brain 2021; 144(3): 863-74.
[http://dx.doi.org/10.1093/brain/awaa443] [PMID: 33829232]
[28]
Jankovic J, Tan EK. Parkinson’s disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020; 91(8): 795-808.
[http://dx.doi.org/10.1136/jnnp-2019-322338] [PMID: 32576618]
[29]
Ataide M, Franco CMR, Lins OG. Daytime sleepiness and Parkinson’s disease: The contribution of the multiple sleep latency test. Sleep Disord 2014; 2014: 1-9.
[http://dx.doi.org/10.1155/2014/767181] [PMID: 25126427]
[30]
Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003; 26(8): 1049-54.
[http://dx.doi.org/10.1093/sleep/26.8.1049] [PMID: 14746389]
[31]
Stefani A, Högl B. Sleep in Parkinson’s disease. Neuropsychopharmacology 2020; 45(1): 121-8.
[http://dx.doi.org/10.1038/s41386-019-0448-y] [PMID: 31234200]
[32]
Chung S, Bohnen NI, Albin RL, Frey KA, Müller MLTM, Chervin RD. Insomnia and sleepiness in Parkinson disease: Associations with symptoms and comorbidities. J Clin Sleep Med 2013; 9(11): 1131-7.
[http://dx.doi.org/10.5664/jcsm.3150] [PMID: 24235893]
[33]
Taximaimaiti R, Luo X, Wang XP. Pharmacological and non-pharmacological treatments of sleep disorders in Parkinson’s disease. Curr Neuropharmacol 2021; 19(12): 2233-49.
[http://dx.doi.org/10.2174/1570159X19666210517115706] [PMID: 33998990]
[34]
Taguchi S, Koide H, Oiwa H, et al. Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson’s disease. PLoS One 2021; 16(7): e0255274.
[http://dx.doi.org/10.1371/journal.pone.0255274] [PMID: 34320022]
[35]
Scanga A, Lafontaine AL, Kaminska M. An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson’s disease. J Clin Sleep Med 2023; 19(6): 1133-44.
[http://dx.doi.org/10.5664/jcsm.10450] [PMID: 36716191]
[36]
Höglund A, Hagell P, Broman JE, Pålhagen S, Sorjonen K, Fredrikson S. A 10-year follow-up of excessive daytime sleepiness in Parkinson’s Disease. Parkinsons Dis 2019; 2019: 1-7.
[http://dx.doi.org/10.1155/2019/5708515] [PMID: 31583073]
[37]
Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005; 65(9): 1442-6.
[http://dx.doi.org/10.1212/01.wnl.0000183056.89590.0d] [PMID: 16275833]
[38]
Jin H, Zhang JR, Shen Y, Liu CF. Clinical significance of rem sleep behavior disorders and other non-motor symptoms of parkinsonism. Neurosci Bull 2017; 33(5): 576-84.
[http://dx.doi.org/10.1007/s12264-017-0164-8] [PMID: 28770440]
[39]
Boucetta S, Salimi A, Dadar M, Jones BE, Collins DL, Dang-Vu TT. Structural brain alterations associated with rapid eye movement sleep behavior disorder in parkinson’s disease. Sci Rep 2016; 6(1): 26782.
[http://dx.doi.org/10.1038/srep26782] [PMID: 27245317]
[40]
Zimansky L, Muntean ML, Leha A, Mollenhauer B, Trenkwalder C, Sixel-Döring F. Incidence and progression of rapid eye movement behavior disorder in early parkinson’s disease. Mov Disord Clin Pract (Hoboken) 2021; 8(4): 534-40.
[http://dx.doi.org/10.1002/mdc3.13168] [PMID: 33977115]
[41]
Kroeger D, Ferrari LL, Petit G, et al. Cholinergic, Glutamatergic, and GABAergic Neurons of the pedunculopontine tegmental nucleus have distinct effects on sleep/wake behavior in mice. J Neurosci 2017; 37(5): 1352-66.
[http://dx.doi.org/10.1523/JNEUROSCI.1405-16.2016] [PMID: 28039375]
[42]
Chan PC, Lee HH, Hong CT, Hu CJ, Wu D. REM sleep behavior disorder (RBD) in dementia with lewy bodies (DLB). Behav Neurol 2018; 2018: 1-10.
[http://dx.doi.org/10.1155/2018/9421098] [PMID: 30018672]
[43]
Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001; 16(4): 622-30.
[http://dx.doi.org/10.1002/mds.1120] [PMID: 11481685]
[44]
Mateo-Montero RC, Pedrera-Mazarro A, Martín-Palomeque G, et al. Clinical and genetical study of a familial form of REM sleep behavior disorder. Clin Neurol Neurosurg 2018; 175: 130-3.
[http://dx.doi.org/10.1016/j.clineuro.2018.09.035] [PMID: 30419424]
[45]
Ferman TJ, Boeve BF, Smith GE, et al. REM sleep behavior disorder and dementia. Neurology 1999; 52(5): 951-7.
[http://dx.doi.org/10.1212/WNL.52.5.951] [PMID: 10102411]
[46]
Mao J, Huang X, Yu J, et al. Association between REM sleep behavior disorder and cognitive dysfunctions in parkinson’s disease: A systematic review and meta-analysis of observational studies. Front Neurol 2020; 11: 577874.
[http://dx.doi.org/10.3389/fneur.2020.577874] [PMID: 33240202]
[47]
Wallace DM, Wohlgemuth WK, Trotti LM, et al. Practical evaluation and management of insomnia in parkinson’s disease: A review. Mov Disord Clin Pract (Hoboken) 2020; 7(3): 250-66.
[http://dx.doi.org/10.1002/mdc3.12899] [PMID: 32258222]
[48]
Xu Z, Anderson KN, Pavese N. Longitudinal studies of sleep disturbances in parkinson’s disease. Curr Neurol Neurosci Rep 2022; 22(10): 635-55.
[http://dx.doi.org/10.1007/s11910-022-01223-5] [PMID: 36018498]
[49]
Xiang Y, Xu Q, Sun Q, et al. Clinical features and correlates of excessive daytime sleepiness in parkinson’s disease. Front Neurol 2019; 10: 121.
[http://dx.doi.org/10.3389/fneur.2019.00121] [PMID: 30837940]
[50]
Ye G, Xu X, Zhou L, Zhao A, Zhu L, Liu J. Evolution patterns of probable REM sleep behavior disorder predicts Parkinson’s disease progression. NPJ Parkinsons Dis 2022; 8(1): 36.
[http://dx.doi.org/10.1038/s41531-022-00303-0] [PMID: 35383198]
[51]
Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Restless legs syndrome and leg motor restlessness in parkinson’s disease. Parkinsons Dis 2015; 2015: 1-9.
[http://dx.doi.org/10.1155/2015/490938] [PMID: 26504610]
[52]
Minibajeva O, Zeltiņa E, Karelis G, Kurjāne N, Ķēniņa V. Clinical symptoms influencing parkinson’s patients’ quality of life in Latvia: A Single-center cohort study. Medicina (Kaunas) 2023; 59(5): 935.
[http://dx.doi.org/10.3390/medicina59050935] [PMID: 37241166]
[53]
Monaghan AS, Hooyman A, Dibble LE, Mehta SH, Peterson DS. Cognitive predictors of responsiveness to reactive step training in people with parkinson’s disease at fall-risk. Neurosci Lett 2023; 817: 137517.
[http://dx.doi.org/10.1016/j.neulet.2023.137517] [PMID: 37832815]
[54]
Colautti L, Iannello P, Silveri MC, Antonietti A. Decision making in Parkinson’s disease: An analysis of the studies using the Iowa Gambling Task. Eur J Neurosci 2021; 54(10): 7513-49.
[http://dx.doi.org/10.1111/ejn.15497] [PMID: 34655122]
[55]
Chen J, Tuersun Y, Yang J, et al. Association of depression symptoms and sleep quality with state-trait anxiety in medical university students in Anhui Province, China: A mediation analysis. BMC Med Educ 2022; 22(1): 627.
[http://dx.doi.org/10.1186/s12909-022-03683-2] [PMID: 35982434]
[56]
de Figueiredo JM, Zhu B, Patel AS, Kohn R, Koo BB, Louis ED. Differential impact of resilience on demoralization and depression in Parkinson disease. Front Psychiatry 2023; 14: 1207019.
[http://dx.doi.org/10.3389/fpsyt.2023.1207019] [PMID: 37559912]
[57]
Diaconu Ş, Falup-Pecurariu C. Personalized assessment of insomnia and sleep quality in patients with parkinson’s disease. J Pers Med 2022; 12(2): 322.
[http://dx.doi.org/10.3390/jpm12020322] [PMID: 35207811]
[58]
Ben Simon E, Walker MP. Sleep loss causes social withdrawal and loneliness. Nat Commun 2018; 9(1): 3146.
[http://dx.doi.org/10.1038/s41467-018-05377-0] [PMID: 30108218]
[59]
Havlikova E, van Dijk JP, Nagyova I, et al. The impact of sleep and mood disorders on quality of life in Parkinson’s disease patients. J Neurol 2011; 258(12): 2222-9.
[http://dx.doi.org/10.1007/s00415-011-6098-6] [PMID: 21614432]
[60]
Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson’s disease sleep scale: A new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73(6): 629-35.
[http://dx.doi.org/10.1136/jnnp.73.6.629] [PMID: 12438461]
[61]
Stavitsky K, Cronin-Golomb A. Sleep quality in Parkinson disease: An examination of clinical variables. Cogn Behav Neurol 2011; 24(2): 43-9.
[http://dx.doi.org/10.1097/WNN.0b013e31821a4a95] [PMID: 21537164]
[62]
Tang X, Yang J, Zhu Y, et al. High PSQI score is associated with the development of dyskinesia in Parkinson’s disease. NPJ Parkinsons Dis 2022; 8(1): 124.
[http://dx.doi.org/10.1038/s41531-022-00391-y] [PMID: 36175559]
[63]
Kumar S, Bhatia M, Behari M. Excessive daytime sleepiness in Parkinson’s disease as assessed by epworth sleepiness scale (ESS). Sleep Med 2003; 4(4): 339-42.
[http://dx.doi.org/10.1016/S1389-9457(03)00105-9] [PMID: 14592307]
[64]
Frazzitta G, Maestri R, Ferrazzoli D, et al. Multidisciplinary intensive rehabilitation treatment improves sleep quality in Parkinson’s disease. J Clin Mov Disord 2015; 2(1): 11.
[http://dx.doi.org/10.1186/s40734-015-0020-9] [PMID: 26788347]
[65]
Mischley LK, Lau RC, Bennett RD. Role of diet and nutritional supplements in Parkinson’s disease progression. Oxid Med Cell Longev 2017; 2017(1): 1-9.
[http://dx.doi.org/10.1155/2017/6405278] [PMID: 29081890]
[66]
Kutscher SJ, Farshidpanah S, Claassen DO. Sleep dysfunction and its management in Parkinson’s disease. Curr Treat Options Neurol 2014; 16(8): 304.
[http://dx.doi.org/10.1007/s11940-014-0304-7] [PMID: 24930678]
[67]
Voysey ZJ, Barker RA, Lazar AS. The Treatment of Sleep Dysfunction in Neurodegenerative Disorders. Neurotherapeutics 2021; 18(1): 202-16.
[http://dx.doi.org/10.1007/s13311-020-00959-7] [PMID: 33179197]
[68]
Humbert M, Findley J, Hernandez-Con M, Chahine LM. Cognitive behavioral therapy for insomnia in Parkinson’s disease: A case series. NPJ Parkinsons Dis 2017; 3(1): 25.
[http://dx.doi.org/10.1038/s41531-017-0027-z] [PMID: 28765835]
[69]
Coe S, Franssen M, Collett J, et al. Physical activity, fatigue, and sleep in people with parkinson’s disease: A secondary per protocol analysis from an intervention trial. Parkinsons Dis 2018; 2018: 1-6.
[http://dx.doi.org/10.1155/2018/1517807] [PMID: 30258564]
[70]
Huang HT, Huang TW, Hong CT. Bright light therapy for parkinson disease: A literature review and meta-analysis of randomized controlled trials. Biology (Basel) 2021; 10(11): 1205.
[http://dx.doi.org/10.3390/biology10111205] [PMID: 34827198]
[71]
Prenger MTM, Madray R, Van Hedger K, Anello M, MacDonald PA. Social symptoms of Parkinson’s disease. Parkinsons Dis 2020; 2020(1): 8846544.
[PMID: 33489081]
[72]
Menza M, Dobkin RD, Marin H, et al. Treatment of insomnia in Parkinson’s disease: A controlled trial of eszopiclone and placebo. Mov Disord 2010; 25(11): 1708-14.
[http://dx.doi.org/10.1002/mds.23168] [PMID: 20589875]
[73]
Rios Romenets S, Creti L, Fichten C, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – A randomized study. Parkinsonism Relat Disord 2013; 19(7): 670-5.
[http://dx.doi.org/10.1016/j.parkreldis.2013.03.003] [PMID: 23561946]
[74]
Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med 2005; 6(5): 459-66.
[http://dx.doi.org/10.1016/j.sleep.2005.04.004] [PMID: 16084125]
[75]
Medeiros CAM, Carvalhedo de Bruin PF, Lopes LA, Magalhães MC, de Lourdes Seabra M, Sales de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. J Neurol 2007; 254(4): 459-64.
[http://dx.doi.org/10.1007/s00415-006-0390-x] [PMID: 17404779]
[76]
Shen Y, Huang JY, Li J, Liu CF. Excessive daytime sleepiness in Parkinson’s Disease. Chin Med J 2018; 131(8): 974-81.
[http://dx.doi.org/10.4103/0366-6999.229889] [PMID: 29664059]
[77]
Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 2003; 18(3): 287-93.
[http://dx.doi.org/10.1002/mds.10390] [PMID: 12621632]
[78]
Högl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25(8): 62-6.
[http://dx.doi.org/10.1093/sleep/25.8.62] [PMID: 12489899]
[79]
Lou JS, Dimitrova DM, Park BS, et al. Using modafinil to treat fatigue in Parkinson disease: A double-blind, placebo-controlled pilot study. Clin Neuropharmacol 2009; 32(6): 305-10.
[http://dx.doi.org/10.1097/WNF.0b013e3181aa916a] [PMID: 19620846]
[80]
Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: Double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76(12): 1636-9.
[http://dx.doi.org/10.1136/jnnp.2005.065870] [PMID: 16291885]
[81]
Postuma RB, Lang AE, Munhoz RP, et al. Caffeine for treatment of Parkinson disease. Neurology 2012; 79(7): 651-8.
[http://dx.doi.org/10.1212/WNL.0b013e318263570d] [PMID: 22855866]
[82]
Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD). Neurology 2017; 89(17): 1795-803.
[http://dx.doi.org/10.1212/WNL.0000000000004568] [PMID: 28954882]
[83]
Büchele F, Hackius M, Schreglmann SR, et al. Sodium oxybate for excessive daytime sleepiness and sleep disturbance in parkinson disease. JAMA Neurol 2018; 75(1): 114-8.
[http://dx.doi.org/10.1001/jamaneurol.2017.3171] [PMID: 29114733]
[84]
Suzuki K, Miyamoto M, Miyamoto T, et al. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: An open-label, 3-month study. J Neurol Sci 2017; 380: 230-3.
[http://dx.doi.org/10.1016/j.jns.2017.07.045] [PMID: 28870576]
[85]
Matsuura K, Kajikawa H, Tabei K, et al. The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson’s disease. Neurosci Lett 2018; 662: 158-61.
[http://dx.doi.org/10.1016/j.neulet.2017.10.018] [PMID: 29031781]
[86]
Lajoie AC, Gu Y, Lim A, Benedetti A, Kaminska M. Adherence to continuous positive airway pressure for the treatment of obstructive sleep apnea in neurodegenerative diseases: A systematic review. Sleep Med Rev 2023; 71: 101836.
[http://dx.doi.org/10.1016/j.smrv.2023.101836] [PMID: 37586145]
[87]
Winkelmann J, Allen RP, Högl B, et al. Treatment of restless legs syndrome: Evidence‐based review and implications for clinical practice (Revised 2017) §. Mov Disord 2018; 33(7): 1077-91.
[http://dx.doi.org/10.1002/mds.27260] [PMID: 29756335]
[88]
Cochen De Cock V. Therapies for restless legs in parkinson’s disease. Curr Treat Options Neurol 2019; 21(11): 56.
[http://dx.doi.org/10.1007/s11940-019-0596-8] [PMID: 31707535]
[89]
Iftikhar IH, Alghothani L, Trotti LM. Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: A comparative meta‐analysis. Eur J Neurol 2017; 24(12): 1446-56.
[http://dx.doi.org/10.1111/ene.13449] [PMID: 28888061]
[90]
Gilat M, Marshall NS, Testelmans D, Buyse B, Lewis SJG. A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: Time for more and larger randomized placebo-controlled trials. J Neurol 2022; 269(1): 125-48.
[http://dx.doi.org/10.1007/s00415-020-10353-0] [PMID: 33410930]
[91]
Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: An american academy of sleep medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med 2023; 19(4): 769-810.
[http://dx.doi.org/10.5664/jcsm.10426] [PMID: 36515150]
[92]
Madrid J, Benninger DH. Non-invasive brain stimulation for Parkinson’s disease: Clinical evidence, latest concepts and future goals: A systematic review. J Neurosci Methods 2021; 347: 108957.
[http://dx.doi.org/10.1016/j.jneumeth.2020.108957] [PMID: 33017643]
[93]
Jenner P, Mori A, Kanda T. Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson’s disease? Parkinsonism Relat Disord 2020; 80: S28-36.
[http://dx.doi.org/10.1016/j.parkreldis.2020.09.022] [PMID: 33349577]
[94]
Leta V, Dafsari HS, Sauerbier A, et al. Personalised advanced therapies in parkinson’s disease: The role of non-motor symptoms profile. J Pers Med 2021; 11(8): 773.
[http://dx.doi.org/10.3390/jpm11080773] [PMID: 34442417]
[95]
Zhang X, Xie A. Improvement of subthalamic nucleus deep brain stimulation in sleeping symptoms in parkinson’s disease: A meta-analysis. Parkinsons Dis 2019; 2019: 1-9.
[http://dx.doi.org/10.1155/2019/6280896] [PMID: 31687125]
[96]
Stefani A, Cerroni R, Pierantozzi M, et al. Deep brain stimulation in Parkinson’s disease patients and routine 6‐OHDA rodent models: Synergies and pitfalls. Eur J Neurosci 2021; 53(7): 2322-43.
[http://dx.doi.org/10.1111/ejn.14950] [PMID: 32853415]
[97]
Baumann-Vogel H, Imbach LL, Sürücü O, et al. The impact of subthalamic deep brain stimulation on sleep–wake behavior: A prospective electrophysiological study in 50 parkinson patients. Sleep 2017; 40(5): zsx033.
[http://dx.doi.org/10.1093/sleep/zsx033] [PMID: 28369624]
[98]
De Fabregues O, Dot J, Abu-Suboh M, et al. Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion. Brain Behav 2017; 7(8): e00758.
[http://dx.doi.org/10.1002/brb3.758] [PMID: 28828219]
[99]
Zibetti M, Rizzone M, Merola A, et al. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease. Acta Neurol Scand 2013; 127(5): e28-32.
[http://dx.doi.org/10.1111/ane.12075] [PMID: 23311399]
[100]
De Cock VC, Dodet P, Leu-Semenescu S, et al. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson’s disease (APOMORPHEE): A multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol 2022; 21(5): 428-37.
[http://dx.doi.org/10.1016/S1474-4422(22)00085-0] [PMID: 35429481]
[101]
Suzuki K. Current update on clinically relevant sleep issues in Parkinson’s disease: A narrative review. J Parkinsons Dis 2021; 11(3): 971-92.
[http://dx.doi.org/10.3233/JPD-202425] [PMID: 33896849]